Olanzapine–samidorphan (Lybalvi) combines the antipsychotic olanzapine with the opioid receptor modulator samidorphan to mitigate olanzapine-associated weight gain. While clinical trials have supported comparable efficacy and improved metabolic outcomes relative to olanzapine alone, data on mood effects remain limited. We report the case of a 40-year-old man with no prior psychiatric history who was psychiatrically hospitalized, and developed clinically significant dysphoric and depressive symptoms shortly after transitioning from a new prescription of olanzapine monotherapy to olanzapine–samidorphan. His depressive symptoms, including anhedonia, amotivation, and fatigue, resolved rapidly upon resumption of olanzapine alone, with no recurrence over 6 months of follow-up. The temporal association and symptom resolution following discontinuation suggest a possible causal relationship. The pharmacologic profile of samidorphan, as a μ-opioid receptor antagonist and partial κ-agonist, may underlie this effect, as κ-receptor activation has been linked to dysphoria and anhedonia. Although large-scale studies of samidorphan have not demonstrated consistent prodepressive effects, individual susceptibility related to opioid receptor signaling may exist. This case highlights the need for clinical vigilance regarding emergent depressive symptoms in patients prescribed olanzapine–samidorphan, particularly those with prior mood vulnerability. Further investigation is warranted to clarify the neurobiological mechanisms and potential risk factors for mood disturbance associated with samidorphan-containing formulations.
Parkerson et al. (Thu,) studied this question.